Rosuvastatin to Decrease Risk of Fracture - JUPITER RCT trial .
This study has been identified as potentially high impact.
OE's AI-driven High Impact metric estimates the influence a paper is likely to have by integrating signals from both the journal in which it is published and the scientific content of the article itself.
Developed using state-of-the-art natural language processing, the OE High Impact model more accurately predicts a study's future citation performance than journal impact factor alone.
This enables earlier recognition of clinically meaningful research and helps readers focus on articles most likely to shape future practice.
Statin therapy and risk of fracture: results from the JUPITER randomized clinical trial
JAMA Intern Med. 2015 Feb;175(2):171-7.Seventeen thousand eight hundred two patients with no history of cardiovascular disease or diabetes but with elevated hs-CRP were randomized to receive rosuvastatin 20 mg daily (n=8,901) or placebo (n=8,901). The primary outcome of interest was incident fracture. Secondary outcomes included subgroup effects by sex and hs-CRP tertiles, as well as site-specific fracture rates. Outcomes were assessed for a median follow-up of 1.9 years. Overall, the results of the study revealed no significant difference in fracture rates between the rosuvastatin and placebo groups (adjusted HR 1.06, 95% CI 0.88–1.28; p=0.53). The study concludes that rosuvastatin does not reduce fracture risk and baseline hs-CRP is not predictive of fractures in this population.
Unlock the Full ACE Report
You have access to 4 more FREE articles this month.
Click below to unlock and view this ACE Reports
Unlock Now
Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidencecontent for as little as $1.99 per week.
Already have an account? Log in
0 of 4 monthly FREE articles unlocked
